Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Cardiol Therapeutics Inc (CRDL.TO)

Cardiol Therapeutics Inc (CRDL.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Cardiol Therapeutics Inc 2265 Upper Middle Road East Suite 602 Oakville ON L6H 0G5 CAN

https://www.cardiolrx.com P: 289-910-0850

Description:

Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.

Key Statistics

Overview:

Market Capitalization, $K 202,165
Shares Outstanding, K 68,998
Annual Sales, $ 0 K
Annual Net Income, $ -28,128 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -9,180 K
60-Month Beta 0.56
% of Institutional Shareholders 5.02%

Growth:

1-Year Return 244.71%
3-Year Return -8.44%
5-Year Return -36.72%
5-Year Revenue Growth 0.00%

Per-Share Information:

Latest Earnings Date N/A
Earnings Per Share ttm -0.47
EPS Growth vs. Prev Year 4.44%
Dividend Payout Ratio 0.00%

CRDL.TO Ratios

Ratio
Price/Earnings ttm N/A
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -92.11%
Return-on-Assets % -72.11%
Profit Margin % 0.00%
Debt/Equity 0.01
Price/Sales N/A
Price/Book 10.08
Book Value/Share 0.29
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar